Last updated on February 2020

Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Noninfectious Uveitis
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Key Inclusion Criteria:

  • Is diagnosed with active noninfectious intermediate-, posterior-, or pan-uveitis
  • Must have active uveitic disease at the Day 1/Baseline visit as defined by the presence of at least 1 of the following parameters in at least one eye despite 2 weeks of maintenance therapy with oral prednisone ( 10 mg/day to 60 mg/day) or an oral corticosteroid equivalent:
  • Active, inflammatory, chorioretinal and/or inflammatory retinal vascular lesion
  • 2+ anterior chamber cells per the Standardization of Uveitis Nomenclature (SUN) criteria
  • 2+ vitreous haze per the National Eye Institute/Standardization of Uveitis Nomenclature (NEI/SUN) criteria
  • No evidence of active tuberculosis (TB), history of prior TB or latent TB meeting the screening criteria

Key Exclusion Criteria:

  • Elevated intraocular pressures and/or severe glaucoma at screening
  • Confirmed or suspected infectious uveitis, including but not limited to infectious uveitis due to TB, cytomegalovirus (CMV), Human T-Lymphotropic Virus Type 1 (HTLV-1), Whipple's disease, Herpes Zoster virus (HZV), Lyme disease, toxoplasmosis and herpes simplex virus (HSV)
  • Adults in whom anti-tumor necrosis factor (TNF) therapy has failed in controlling uveitis (as determined by the investigator) or previous exposure to any biologic therapy (except intravitreal anti-vascular endothelial growth factor (VEGF) therapy) with a potential therapeutic impact on noninfectious uveitis within 90 days of Day 1/ Baseline are not eligible to participate

Note: Other protocol defined Inclusion/ Exclusion criteria may apply.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.